^
Association details:
| Biomarker: | EGFR overexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | navitoclax (ABT 263) (Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor) + serclutamab talirine (ABBV-321) (DNA replication inhibitor, EGFR-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
Published date:
11/30/2020
Excerpt:
The pre-clinical efficacy of combined treatments was evaluated in multiple patient-derived xenograft (PDX) models of TNBC….Navitoclax plus ABBV-321, an EGFR-targeted ADC that displays more effective wild-type EGFR-targeting, elicited more significant tumor growth inhibition and regressions in the two highest EGFR-expressing models evaluated.
DOI:
10.1186/s13058-020-01374-8
